Thomas Wingo

Dr. Thomas Wingo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

13 April 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EJErik C. B. Johnson
Erik C. B. Johnson
EDEric Dammer
Eric Dammer
DDDuc M. Duong
Duc M. Duong
LPLingyan Ping
Lingyan Ping
MZMaotian Zhou
Maotian Zhou
NSNicholas T. Seyfried
Nicholas T. Seyfried

3 February 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
EJErik C. B. Johnson
Erik C. B. Johnson
ECE. Kathleen Carter
E. Kathleen Carter
EDEric Dammer
Eric Dammer
DDDuc M. Duong
Duc M. Duong
EGEkaterina S. Gerasimov
Ekaterina S. Gerasimov
NSNicholas T. Seyfried
Nicholas T. Seyfried
The biological processes that are disrupted in the Alzheimer’s disease (AD) brain remain incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain tissues to reveal new AD-related protein co-expression modules that were highly preserved across cohorts and brain regions. Nearly half of the protein co-expression modules, including modules significantly altered in AD, were not observed in RNA networks from the same cohorts and brain regions, highlighting the proteopathic nature of AD. Two such AD-associated modules unique to the proteomic network included a module related to MAPK signaling and metabolism and a module related to the matrisome. The matrisome module was influenced by the APOE ε4 allele but was not related to the rate of cognitive decline after adjustment for neuropathology. By contrast, the MAPK/metabolism module was strongly associated with the rate of cognitive decline. Disease-associated modules unique to the proteome are sources of promising therapeutic targets and biomarkers for AD.

28 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AWAliza Wingo
Aliza Wingo
YLYue Liu
Yue Liu
EGEkaterina S. Gerasimov
Ekaterina S. Gerasimov
JGJake Gockley
Jake Gockley
BLBenjamin A. Logsdon
Benjamin A. Logsdon
TWThomas Wingo
Thomas Wingo

3 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ZXZihui Xu
Zihui Xu
MPMickael Poidevin
Mickael Poidevin
XLXuekun Li
Xuekun Li
YLYujing Li
Yujing Li
LSLiqi Shu
Liqi Shu
PJPeng Jin
Peng Jin
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share phenotypic and pathologic overlap. Recently, an expansion of GGGGCC repeats in the first intron of C9orf72 was found to be a common cause of both illnesses; however, the molecular pathogenesis of this expanded repeat is unknown. Here we developed both Drosophila and mammalian models of this expanded hexanucleotide repeat and showed that expression of the expanded GGGGCC repeat RNA (rGGGGCC) is sufficient to cause neurodegeneration. We further identified Pur α as the RNA-binding protein of rGGGGCC repeats and discovered that Pur α and rGGGGCC repeats interact in vitro and in vivo in a sequence-specific fashion that is conserved between mammals and Drosophila . Furthermore, overexpression of Pur α in mouse neuronal cells and Drosophila mitigates rGGGGCC repeat-mediated neurodegeneration, and Pur α forms inclusions in the fly eye expressing expanded rGGGGCC repeats, as well as in cerebellum of human carriers of expanded GGGGCC repeats. These data suggest that expanded rGGGGCC repeats could sequester specific RNA-binding protein from their normal functions, ultimately leading to cell death. Taken together, these findings suggest that the expanded rGGGGCC repeats could cause neurodegeneration, and that Pur α may play a role in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia.

19 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLiuhua Shi
Liuhua Shi
KSKyle Steenland
Kyle Steenland
HLHaomin Li
Haomin Li
PLPengfei Liu
Pengfei Liu
YZYuhan Zhang
Yuhan Zhang
JSJoel Schwartz
Joel Schwartz
Air pollution may increase risk of Alzheimer’s disease and related dementias (ADRD) in the U.S., but the extent of this relationship is unclear. Here, we constructed two national U.S. population-based cohorts of those aged ≥65 from the Medicare Chronic Conditions Warehouse (2000–2018), combined with high-resolution air pollution datasets, to investigate the association of long-term exposure to ambient fine particulate matter (PM2.5), nitrogen dioxide (NO2), and ozone (O3) with dementia and AD incidence, respectively. We identified ~2.0 million incident dementia cases (N = 12,233,371; dementia cohort) and ~0.8 million incident AD cases (N = 12,456,447; AD cohort). Per interquartile range (IQR) increase in the 5-year average PM2.5 (3.2 µg/m3), NO2 (11.6 ppb), and warm-season O3 (5.3 ppb) over the past 5 years prior to diagnosis, the hazard ratios (HRs) were 1.060 (95% confidence interval [CI]: 1.054, 1.066), 1.019 (95% CI: 1.012, 1.026), and 0.990 (95% CI: 0.987, 0.993) for incident dementias, and 1.078 (95% CI: 1.070, 1.086), 1.031 (95% CI: 1.023, 1.039), and 0.982 (95%CI: 0.977, 0.986) for incident AD, respectively, for the three pollutants. For both outcomes, concentration-response relationships for PM2.5 and NO2 were approximately linear. Our study suggests that exposures to PM2.5 and NO2 are associated with incidence of dementia and AD.